APPLYING REWIND CVD CRITERIA TO SUSTAIN 6 AND PIONEER 6: AN EXPLORATORY ANALYSIS OF CV OUTCOMES WITH SEMAGLUTIDE

In the REWIND cardiovascular (CV) outcomes trial (CVOT), the glucagon-like peptide-1 receptor agonist (GLP-1RA) dulaglutide reduced CV risk vs placebo in patients with type 2 diabetes (T2D) and elevated CV risk. The SUSTAIN 6 ([NCT01720446][1]) and PIONEER 6 ([NCT02692716][2]) CVOTs of the GLP-1RA